Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|February 11, 2021
Clinical application of genomics in Waldenström macroglobulinemiaAndrew R Branagan, Mathew Lei, Steven P Treon, et al.Expert Review of Anticancer Therapy|April 11, 2022
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemiaShayna Sarosiek, David Sermer, Andrew R Branagan, et al.Clinical Lymphoma, Myeloma & Leukemia|March 27, 2022
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström MacroglobulinemiaDavid Sermer, Shayna Sarosiek, Andrew R Branagan, et al.Leukemia & Lymphoma|January 22, 2026
Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemiaShayna Sarosiek, Jorge J Castillo, Zachary R Hunter, et al.The New England Journal of Medicine|February 11, 2016
Clonal Immunoglobulin against Lysolipids in the Origin of MyelomaShiny Nair, Andrew R Branagan, Jun Liu, et al.Seminars in Oncology|April 30, 2003
Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaDonna Weber, Steven P Treon, Christos Emmanouilides, et al.Clinical Lymphoma|January 8, 2005
Clinical responses to sildenafil in Waldenstrom's macroglobulinemiaSteven P Treon, Olivier Tournilhac, Andrew R Branagan, et al.Blood Cancer Journal|October 27, 2021
Lifestyle considerations in multiple myelomaYael N Shapiro, Jeffrey M Peppercorn, Andrew J Yee, et al.Blood Advances|July 17, 2025
Ibrutinib plus rituximab versus ibrutinib monotherapy in patients with Waldenström macroglobulinemia: A pooled analysisAlberto Guijosa, Andres Ramirez-Gamero, Shayna Sarosiek, et al.Blood Cancer Journal|April 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-TJoshua N Gustine, Narsis Attar, Benjamin R Puliafito, et al.Pageof 6